Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France
Case Report
Capecitabine-induced hypertriglyceridemia (CIHT): case report of an unsuspected and misunderstood adverse event!
Author(s): Francois Poumeaud*, Arthur Glenet, Marion Montastruc, Blandine Delaunay, Beatrice Laudet and Florence Dalenc
Severe adverse events with both 5-Fluorouracile (5-FU) and capecitabine, one of its prodrugs, have been extensively studied and primarily related to a partial or complete Dihydropyrimidine Dehydrogenase (DPD) deficiency. However, rare and atypical side effects such as hypertriglyceridemia might still occur in the absence of DPD deficiency. We report the case of a 61- year-old woman with early-stage triple negative breast cancer treated with adjuvant capecitabine. While having no phenotypic DPD deficiency, she developed severe Capecitabine-Induced Hypertriglyceridemia (CIHT, 49 g/L) after four treatment cycles at a reduced dose (1000 mg/m2 ). Notably, the patient experienced only grade I hand-foot syndrome at initiation with no other capecitabine-associated toxicities. CIHT spontaneously resolved after interrupting treatment with no relapse and no further treatment. We suggest that Car.. View More»